- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Hereditary transthyretin-mediated (hATTR) amyloidosis
- Meeting Date: November 2024
- Public Summary Document (PSD) November 2024 PBAC Meeting - (PDF 830KB)
- Public Summary Document (PSD) November 2024 PBAC Meeting - (Word 326KB)
Vutrisiran – November 2024
Vutrisiran; Injection 25 mg (as sodium) in 0.5 mL pre filled syringe; Amvuttra®
Last updated
30 May 2025